ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) dosed the first patient in a phase III clinical trial of IMM01 (Timdarpacept) in combination with azacitidine for the first-line treatment of chronic myelomonocytic leukemia, a Tuesday bourse filing said.
Shares of the pharma firm closed nearly 16% higher on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments